257 related articles for article (PubMed ID: 34125178)
21. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
22. Polycomb complexes redundantly maintain epidermal stem cell identity during development.
Cohen I; Bar C; Liu H; Valdes VJ; Zhao D; Galbo PM; Silva JM; Koseki H; Zheng D; Ezhkova E
Genes Dev; 2021 Mar; 35(5-6):354-366. PubMed ID: 33602871
[TBL] [Abstract][Full Text] [Related]
23. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.
Maude SL; Dolai S; Delgado-Martin C; Vincent T; Robbins A; Selvanathan A; Ryan T; Hall J; Wood AC; Tasian SK; Hunger SP; Loh ML; Mullighan CG; Wood BL; Hermiston ML; Grupp SA; Lock RB; Teachey DT
Blood; 2015 Mar; 125(11):1759-67. PubMed ID: 25645356
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas.
Piunti A; Hashizume R; Morgan MA; Bartom ET; Horbinski CM; Marshall SA; Rendleman EJ; Ma Q; Takahashi YH; Woodfin AR; Misharin AV; Abshiru NA; Lulla RR; Saratsis AM; Kelleher NL; James CD; Shilatifard A
Nat Med; 2017 Apr; 23(4):493-500. PubMed ID: 28263307
[TBL] [Abstract][Full Text] [Related]
26. Polycomb deficiency drives a FOXP2-high aggressive state targetable by epigenetic inhibitors.
Chen F; Byrd AL; Liu J; Flight RM; DuCote TJ; Naughton KJ; Song X; Edgin AR; Lukyanchuk A; Dixon DT; Gosser CM; Esoe DP; Jayswal RD; Orkin SH; Moseley HNB; Wang C; Brainson CF
Nat Commun; 2023 Jan; 14(1):336. PubMed ID: 36670102
[TBL] [Abstract][Full Text] [Related]
27. Morphine leads to global genome changes in H3K27me3 levels via a Polycomb Repressive Complex 2 (PRC2) self-regulatory mechanism in mESCs.
Muñoa-Hoyos I; Halsall JA; Araolaza M; Ward C; Garcia I; Urizar-Arenaza I; Gianzo M; Garcia P; Turner B; Subirán N
Clin Epigenetics; 2020 Nov; 12(1):170. PubMed ID: 33168052
[TBL] [Abstract][Full Text] [Related]
28. The Multiple Facets of PRC2 Alterations in Cancers.
Wassef M; Margueron R
J Mol Biol; 2017 Jun; 429(13):1978-1993. PubMed ID: 27742591
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic Cooperativity as a Therapeutic Vulnerability in Cancer.
Kazansky Y; Kentsis A
Cancer Res; 2023 Dec; 83(23):3827-3829. PubMed ID: 38037453
[TBL] [Abstract][Full Text] [Related]
30. p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia.
Davies C; Hogarth LA; Dietrich PA; Bachmann PS; Mackenzie KL; Hall AG; Lock RB
J Biol Chem; 2011 Oct; 286(43):37639-50. PubMed ID: 21903579
[TBL] [Abstract][Full Text] [Related]
31. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.
Peirs S; Matthijssens F; Goossens S; Van de Walle I; Ruggero K; de Bock CE; Degryse S; Canté-Barrett K; Briot D; Clappier E; Lammens T; De Moerloose B; Benoit Y; Poppe B; Meijerink JP; Cools J; Soulier J; Rabbitts TH; Taghon T; Speleman F; Van Vlierberghe P
Blood; 2014 Dec; 124(25):3738-47. PubMed ID: 25301704
[TBL] [Abstract][Full Text] [Related]
32. The Role of Polycomb Repressive Complex in Malignant Peripheral Nerve Sheath Tumor.
Zhang X; Murray B; Mo G; Shern JF
Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32182803
[TBL] [Abstract][Full Text] [Related]
33. Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation.
Kim R; Boissel N; Touzart A; Leguay T; Thonier F; Thomas X; Raffoux E; Huguet F; Villarese P; Fourrage C; Passini L; Hunault M; Lepretre S; Chevallier P; Braun T; Lhéritier V; Chantepie S; Maury S; Escoffre M; Tavernier E; Chalandon Y; Graux C; Macintyre E; Ifrah N; Asnafi V; Dombret H; Lhermitte L;
Leukemia; 2020 Jul; 34(7):1730-1740. PubMed ID: 31992840
[TBL] [Abstract][Full Text] [Related]
34. Senescent stromal cell-induced divergence and therapeutic resistance in T cell acute lymphoblastic leukemia/lymphoma.
Habiel DM; Krepostman N; Lilly M; Cavassani K; Coelho AL; Shibata T; Elenitoba-Johnson K; Hogaboam CM
Oncotarget; 2016 Dec; 7(50):83514-83529. PubMed ID: 27835864
[TBL] [Abstract][Full Text] [Related]
35. Acute myeloid leukemia requires Hhex to enable PRC2-mediated epigenetic repression of Cdkn2a.
Shields BJ; Jackson JT; Metcalf D; Shi W; Huang Q; Garnham AL; Glaser SP; Beck D; Pimanda JE; Bogue CW; Smyth GK; Alexander WS; McCormack MP
Genes Dev; 2016 Jan; 30(1):78-91. PubMed ID: 26728554
[TBL] [Abstract][Full Text] [Related]
36. IMITATION SWITCH is required for normal chromatin structure and gene repression in PRC2 target domains.
Kamei M; Ameri AJ; Ferraro AR; Bar-Peled Y; Zhao F; Ethridge CL; Lail K; Amirebrahimi M; Lipzen A; Ng V; Grigoriev IV; Schmitz RJ; Liu Y; Lewis ZA
Proc Natl Acad Sci U S A; 2021 Jan; 118(4):. PubMed ID: 33468665
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic silencing of SOCS5 potentiates JAK-STAT signaling and progression of T-cell acute lymphoblastic leukemia.
Sharma ND; Nickl CK; Kang H; Ornatowski W; Brown R; Ness SA; Loh ML; Mullighan CG; Winter SS; Hunger SP; Cannon JL; Matlawska-Wasowska K
Cancer Sci; 2019 Jun; 110(6):1931-1946. PubMed ID: 30974024
[TBL] [Abstract][Full Text] [Related]
38. PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer.
Nagarsheth N; Peng D; Kryczek I; Wu K; Li W; Zhao E; Zhao L; Wei S; Frankel T; Vatan L; Szeliga W; Dou Y; Owens S; Marquez V; Tao K; Huang E; Wang G; Zou W
Cancer Res; 2016 Jan; 76(2):275-82. PubMed ID: 26567139
[TBL] [Abstract][Full Text] [Related]
39. Indispensable epigenetic control of thymic epithelial cell development and function by polycomb repressive complex 2.
Barthlott T; Handel AE; Teh HY; Wirasinha RC; Hafen K; Žuklys S; Roch B; Orkin SH; de Villartay JP; Daley SR; Holländer GA
Nat Commun; 2021 Jun; 12(1):3933. PubMed ID: 34168132
[TBL] [Abstract][Full Text] [Related]
40. Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
Neff T; Sinha AU; Kluk MJ; Zhu N; Khattab MH; Stein L; Xie H; Orkin SH; Armstrong SA
Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5028-33. PubMed ID: 22396593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
